Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staphylococcus and Neisseria Tablets in Acute Exacerbation of COPD
NCT05543343Phase 3Unknown
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of staphylococcus albus + neisseria catarrhalis in chronic obstructive pulmonary disease (COPD) (3 arms). Primary endpoint: Number of acute exacerbations of chronic obstructive pulmonary disease in 1 year. Status: unknown.
02
Drugs
staphylococcus albus + neisseria catarrhalis
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05543343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543343.